SynthesisFrontiers in medicine2025
Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe ulcerative colitis: a meta-analysis based on randomized controlled trials.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Stratified by baseline corticosteroid use: which advanced therapy works best for whom in ulcerative colitis?Frontiers in medicine · 2026Pooled it
- Trained immunity in inflammatory bone disease: a bibliometric and literature-level text-mining analysis.Frontiers in immunology · 2026Pooled it
- Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn's Disease: Current Evidence and Future Perspectives.Journal of clinical medicine · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin-23 (IL-23) plays a central role in the pathogenesis of ulcerative colitis (UC) by promoting Th17-mediated intestinal inflammation. While monoclonal antibodies targeting the IL-23p19 subunit have shown promise in clinical trials, the overall efficacy and safety of IL-23 inhibitors in moderate to severe UC remain to be comprehensively quantified. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating the efficacy and safety of IL-23p19 inhibitors-including mirikizumab, guselkumab, and risankizumab-in adults with moderate to severe UC. A comprehensive literature search was performed in PubMed, Embase, Web of Science, and Cochrane Library through February 2025. Primary outcomes included clinical remission and clinical response during induction; secondary outcomes included endoscopic remission and adverse events. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Results: Six RCTs encompassing 3,640 patients were included. IL-23 inhibitors significantly improved clinical remission during induction compared to placebo (RR = 2.45; 95% CI: 2.07-2.90; Conclusion: IL-23p19 inhibitors are effective and well tolerated in inducing and maintaining remission in patients with moderate to severe UC, including those with prior treatment failure. These findings support their use as a valuable therapeutic option in the evolving management landscape of UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.